Fulltext

Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases

Mehta M 1 , Deeksha 1 , Tewari D 1 , Gupta G 2 , Awasthi R 3 , Singh H 4 Show all authors , Pandey P 5 , Chellappan DK 6 , Wadhwa R 7 , Collet T 8 , Hansbro PM 9 , Kumar SR 10 , Thangavelu L 10 , Negi P 11 , Dua K 12 , Satija S 13

Affiliations 

  • 1 School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India
  • 2 School of Phamacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India
  • 3 Amity School of Pharmacy, Amity University, Noida, Uttar Pradesh, India
  • 4 National Medicinal Plants Board, Ministry of AYUSH, New Delhi, India
  • 5 Department of Pharmaceutical Sciences, Shri Baba Mastnath University, Rohtak, Haryana, 124001, India
  • 6 Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, 57000, Malaysia
  • 7 Faculty of Life Science and Biotechnology, South Asian University, Akbar Bhawan, Chanakyapuri, New Delhi, 110021, India
  • 8 Indigenous Medicines Group, Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
  • 9 Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050 Australia; School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia
  • 10 Nanobiomedicine Lab, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, 600077, Tamil Nadu, India
  • 11 School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, India
  • 12 Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050 Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia. Electronic address: Kamal.Dua@uts.edu.au
  • 13 School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India. Electronic address: saurabh.21958@lpu.co.in
Chem Biol Interact, 2019 Aug 01;308:206-215.
PMID: 31136735 DOI: 10.1016/j.cbi.2019.05.028

Abstract

Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications